Frontiers in Molecular Biosciences (Dec 2023)

LncRNAs in non-small cell lung cancer: novel diagnostic and prognostic biomarkers

  • Jiang Fu,
  • Jiang Fu,
  • Li Yu,
  • Li Yu,
  • Hang Yan,
  • Hang Yan,
  • Shengjie Tang,
  • Zixu Wang,
  • Zixu Wang,
  • Tingting Dai,
  • Tingting Dai,
  • Haoyu Chen,
  • Haoyu Chen,
  • Song Zhang,
  • Song Zhang,
  • Haiyang Hu,
  • Haiyang Hu,
  • Tao Liu,
  • Shoujun Tang,
  • Rong He,
  • Haining Zhou,
  • Haining Zhou,
  • Haining Zhou,
  • Haining Zhou

DOI
https://doi.org/10.3389/fmolb.2023.1297198
Journal volume & issue
Vol. 10

Abstract

Read online

Non-small cell lung cancer (NSCLC) is one of the main causes of cancer-related death worldwide, with a serious impact on human health and life. The identification of NSCLC at an early stage is a formidable task that frequently culminates in a belated diagnosis. LncRNA is a kind of noncoding RNA with limited protein-coding capacity, and its expression is out of balance in many cancers, especially NSCLC. A large number of studies have reported that lncRNA acts a vital role in regulating angiogenesis, invasion, metastasis, and the proliferation and apoptosis of tumor cells, affecting the occurrence and development of NSCLC. Abundant evidence demonstrates that lncRNAs may serve as potential biomarkers for NSCLC diagnosis and prognosis. In this review, we summarize the latest progress in characterizing the functional mechanism of lncRNAs involved in the development of NSCLC and further discuss the role of lncRNAs in NSCLC therapy and chemotherapy resistance. We also discuss the advantages, limitations, and challenges of using lncRNAs as diagnostic or prognostic biomarkers in the management of NSCLC.

Keywords